Mohammed S El-Awady1, Ghada M Suddek. 1. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.
Abstract
OBJECTIVES: The aim of this work was to explore possible effects of agmatine, an endogenous inhibitor of inducible nitric oxide synthase (iNOS), against hypercholesterolemia-induced lipid profile changes and endothelial dysfunction. METHODS: Hypercholesterolemia was induced by feeding rabbits with a high-cholesterol diet (HCD, 0.5%) for 8 weeks. Another HCD-fed group was orally administered agmatine (10 mg/kg/day) during weeks 5 through 8. Serum lipid profile, malondialdehyde (MDA), nitric oxide (NO) and lactate dehydrogenase (LDH) were determined. Aorta was isolated to analyse vascular reactivity, atherosclerotic lesions and intima/media (I/M) ratio. KEY FINDINGS: HCD induced a significant increase in serum total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), triglycerides and high-density lipoprotein cholesterol (HDL-C). Agmatine administration significantly decreased HCD-induced elevations in serum TC and LDL-C, MDA, LDH and NO while significantly increased HDL-C levels. Additionally, agmatine significantly protected against HCD-induced attenuation of rabbit aortic endothelium-dependent relaxation to acetylcholine. HCD and agmatine did not significantly influence aortic endothelium-independent relaxation to sodium nitroprusside. Moreover, agmatine significantly reduced the elevation in aortic atherosclerotic lesion area and I/M ratio. CONCLUSIONS: This study is the first to reveal that agmatine has the ability to ameliorate hypercholesterolemia-induced lipemic-oxidative and endothelial function injuries possibly by its antioxidant potential and/or iNOS inhibition.
OBJECTIVES: The aim of this work was to explore possible effects of agmatine, an endogenous inhibitor of inducible nitric oxide synthase (iNOS), against hypercholesterolemia-induced lipid profile changes and endothelial dysfunction. METHODS:Hypercholesterolemia was induced by feeding rabbits with a high-cholesterol diet (HCD, 0.5%) for 8 weeks. Another HCD-fed group was orally administered agmatine (10 mg/kg/day) during weeks 5 through 8. Serum lipid profile, malondialdehyde (MDA), nitric oxide (NO) and lactate dehydrogenase (LDH) were determined. Aorta was isolated to analyse vascular reactivity, atherosclerotic lesions and intima/media (I/M) ratio. KEY FINDINGS:HCD induced a significant increase in serum total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), triglycerides and high-density lipoprotein cholesterol (HDL-C). Agmatine administration significantly decreased HCD-induced elevations in serum TC and LDL-C, MDA, LDH and NO while significantly increased HDL-C levels. Additionally, agmatine significantly protected against HCD-induced attenuation of rabbit aortic endothelium-dependent relaxation to acetylcholine. HCD and agmatine did not significantly influence aortic endothelium-independent relaxation to sodium nitroprusside. Moreover, agmatine significantly reduced the elevation in aortic atherosclerotic lesion area and I/M ratio. CONCLUSIONS: This study is the first to reveal that agmatine has the ability to ameliorate hypercholesterolemia-induced lipemic-oxidative and endothelial function injuries possibly by its antioxidant potential and/or iNOS inhibition.
Authors: Omnia A A Nour; George S G Shehatou; Mona Abdel Rahim; Mohammed S El-Awady; Ghada M Suddek Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2018-07-30 Impact factor: 3.000
Authors: Maha H Sharawy; Mohammed S El-Awady; Nirmeen Megahed; Nariman M Gameil Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2015-10-08 Impact factor: 3.000
Authors: Ahmed R El-Sheakh; Hamdy A Ghoneim; Ghada M Suddek; El-Sayed M Ammar Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2015-09-04 Impact factor: 3.000
Authors: Anna Wiśniewska; Rafał Olszanecki; Justyna Totoń-Żurańska; Katarzyna Kuś; Aneta Stachowicz; Maciej Suski; Anna Gębska; Mariusz Gajda; Jacek Jawień; Ryszard Korbut Journal: Int J Mol Sci Date: 2017-08-04 Impact factor: 5.923
Authors: E N Burrage; E Aboaziza; L Hare; S Reppert; J Moore; W T Goldsmith; E E Kelley; A Mills; D Dakhlallah; P D Chantler; I M Olfert Journal: Am J Physiol Heart Circ Physiol Date: 2021-06-25 Impact factor: 5.125